Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a plant compound help exercise recharge older Women's cells?

NCT ID NCT07878741

Knowledge-focused Sponsor: University of Copenhagen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 16, 2026 · Last updated Oct 16, 2026

Summary

Researchers at the University of Copenhagen are studying whether red clover isoflavone supplements boost the heart and blood vessel benefits of exercise in postmenopausal women. About 60 women aged 45 to 60 will join, including premenopausal women as a comparison group. Postmenopausal participants take either isoflavones or a placebo for four weeks before and during an eight-week supervised exercise program. The team measures blood vessel function, muscle cell energy, fitness, and menopause symptoms to see how menopause changes the body's response to training.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
red clover isoflavone supplement
What this could lead to
If isoflavones help, this could point to a simple supplement that makes exercise work better for postmenopausal women's blood vessels and cells.
What could go wrong
This is a small, early study of 60 women, so any effect may be modest or not hold up in larger groups. Isoflavones can also act like weak estrogens, which may not suit everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Oct 2027

An estimate. Start dates often move.

Expected to finish

Jun 2035

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 to 61 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Women aged ≥45 and \<61 years. * Either \* * \*Regular menstrual cycles (premenopausal group), or * \*More than 5 years since the last menstrual period (postmenopausal groups). * Body mass index (BMI) between 18 and 35 kg/m². * Able to provide informed consent and comply with study procedures. Exclusion Criteria: * Current smoking. * Use of menopausal hormone therapy within the previous 12 months. * Consumption of isoflavones through diet or supplements within the previous 12 months. * Chronic disease or medical condition, including diabetes mellitus, cardiovascular disease, polycystic ovary syndrome (PCOS), or endometriosis. * Active cancer or cancer diagnosis within the previous 5 years. * Use of medication for hypertension, hypercholesterolemia, diabetes, obesity, or depression. * Ovariectomy * Highly physically active lifestyle, defined as more than 3 hours per week of structured moderate-to-vigorous exercise during the previous year, including activities such as running, cycling, or high-intensity team sports.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Exercise adaptation are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Exercise adaptation Menopause Mitochondrial alteration Vascular function in healthy volunteers

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Department of Nutrition, Exercise and Sports

    Copenhagen, Storkøbenhavn, 2200, Denmark

  • Faculty of Medical and Health Sciences

    Copenhagen, 2200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.